Sawai Group Holdings Co., Ltd. (SWGHF)
Sawai Group Holdings Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Osaka, OS, JP. The stock last traded at $11.52, up 0.00% on the session, giving a market capitalisation of $1.33B. On trailing twelve-month figures it carries a trailing P/E of 17.84, a net margin of 5.2%. Its beta of 0.03 implies it has historically moved less than the broad market.
Sawai Group Holdings Co., Ltd., along with its subsidiaries, specializes in the research, development, manufacture, and commercialization of generic pharmaceuticals, primarily serving markets in Japan and the United States. The company's extensive portfolio encompasses a variety of generic medications, available in diverse dosage forms such as tablets, capsules, injectables, and liquid formulations (including syrups, ophthalmic, and nasal solutions). These address numerous therapeutic categories, including cardiovascular, gastro-intestinal, central nervous system, metabolic, anti-infective, anti-allergic, and anti-cancer treatments, in addition to vitamin preparations. Sawai distributes its generic products through a network that includes distributors, wholesalers, and retailers across Japan and the United States. Established in 1929, the firm maintains its headquarters in Osaka, Japan.
Sawai Group Holdings Co., Ltd. is most often compared with the following Healthcare names: